Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Below is a list of SINAPPS Group studies both current and closed


Ongoing studies 

 

SINAPPS2 Logo

STUDY OF IMMUNOLOGY IN ANTIBODY POSITIVE PSYCHOSIS 2 (SINAPPS2)

The SINAPP2 trial is a randomised, placebo-controlled clinical trial, investigating the efficacy and safety of immunotherapy as a treatment for symptoms of psychosis in patients with anti-neuronal membrane antibodies.

Click here for more information about SINAPPS2.

 

Prevalence of Pathogenic Antibodies in Psychosis 2 (PPiP2)

The aim of the PPiP2 study is to assess large number of people suffering from psychosis and identify those with anti-neuronal membrane antibodies in their serum which might be causing their illness. Participants with anti-neuronal membrane antibodies will be invited to take part in the SINAPPS2 trial.

Click here for more information about PPIP2 and click here to get involved.

PIPP2 Logo

CLOSED STUDIES

SINAPPS2 Logo purple/blue circle showing electrical brain activity with the words SINAPPS2 below

STUDY OF IMMUNOLOGY IN ANTIBODY POSITIVE PSYCHOSIS 1 (SINAPPS1)

 SINAPPS1 was a phase-one open label study and it investigated the feasibility of delivering immunotherapy to patients with psychosis in a general hospital setting. The study was conducted from October 2015 to July 2017.

Click here for more information about SINAPPS1 and click here to read published findings.

PREVALENCE OF PATHOGENIC ANTIBODIES IN PSYCHOSIS 1 (PPIP1)

The PPiP1 study investigated prevalence of patients with anti-neuronal membrane antibodies included who were experiencing their first episode of psychosis in comparison with a group of healthy participants. The study was conducted from January 2013 to December 2014.

Click here for more information about PPiP1 and click here to read published findings.

PIPP2 Logo